numares AG achieves key milestone: identifies candidate metabolomic network for bladder cancer diagnostics

Urinary bladder carcinoma is among the most common types of cancer with approximately 350,000 new cases per year. Men are significantly more often (3.8 times) affected than women. In Europe about 118,000 new cases were discovered in 2012. In the US there is an estimation of 80,000 new cases and 17,000 deaths by bladder cancer in 2017. 

Bladder cancer is mostly associated with quite unspecific signs and symptoms, such as blood in the urine. If medical anamnesis and ultrasonic examination do not reveal the cause of the hematuria, as a next step a cystoscopy is recommended. 

The innovative approach to use biomarker networks for diagnostic purposes becomes increasingly relevant for several further medical questions, which cannot be addressed by appropriate diagnostic solutions so far. It is numares’ mission to fulfill those unmet diagnostic needs by developing products for its NMR-based AXINON^® IVD system. It is reflected by the company’s product pipeline. To achieve its mission, numares developed its proprietary Magnetic Group Signaling (MGS^®) technology as a prerequisite and employs machine learning techniques (also known as artificial intelligence) to process the large amount of data and to identify metabolomic biomarker networks.

Nuclear Magnetic Resonance (NMR) has long been used as a research tool, in particular for determining the structure of chemical compounds. In the past, this technology was too complex to be used in metabolomics-based medical research or diagnostics due to several technical limitations. numares developed its proprietary Magnetic Group Signaling (MGS^®) technology to enable NMR to answer demanding questions in metabolomics. With MGS^®, important prerequisites like standardization and qualification can be fulfilled through technical processes and procedures. For the first time systematic processing and use of diagnostic information from the metabolism is possible. Thanks to MGS^®, numares’ in vitro diagnostic system (IVD) AXINON^® is able to generate reliable and reproducible data of highest quality – independent of the NMR device or the user. This enables fully automated analysis of patient samples without any human intervention. 

Numares Health AG, based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolics data to develop advanced analytical test tests for high-throughput use in clinical diagnostics and life science research. The AXINON^® in-vitro diagnostics (IVD) system employs nuclear magnetic resonance (NMR) spectroscopy to evaluate metabolic constellations. The IVDs based on this metabolic network provide physicians with valuable insights on patient disease status. Magnetic Group Signaling (MGS^®) is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests stand as an important pillar in precision medicine to address unmet needs in cardiovascular diseases, nephrology, oncology and neurology. You will find more information at www.numares-health.com.